Levels of Nitric Oxide Metabolites and Myeloperoxidase in Subjects with Type 2 Diabetes Mellitus on Metformin Therapy *

Abstract

Introduction Endothelial dysfunction is involved in the pathogenesis of insulin resistance, diabetes mellitus type 2, diabetic complications and preceded clinical manifestation of cardiovascular complications. Increased myeloperoxidase activity has been linked to a number of pathologies with compelling evidence in initiation and progression of inflammatory events. The aim of this study was to compare concentrations of metabolite nitric oxide and myeloperoxidase in the plasma of diabetes mellitus type 2 patients on metformin therapy, without clinical signs of cardiovascular disease and healthy subjects, as well as evaluation of concentrations of analytes in association with glycemic control.

Materials and methods Forty four study subjects with diabetes mellitus type 2 and thirty healthy subjects were included in this study. The concentration of myeloperoxidase was determined by enzyme-linked immunosorbent assay, the concentration of nitrate and nitrite with high performance liquid chromatography method. Student's t test, Mann-Whitney U test, Chi-square test and Fisher's exact test were used for statistical analysis.

Results The mean concentration of myeloperoxidase was significantly higher in the diabetic group compared to the control group (16.2±4.9 vs. 3.7±1.8; P<0.001).The nitrite concentration was comparable in both groups while the concentration of nitrate was significantly higher in the diabetic group (41.2 [42.9] vs 31.9 [23]; P=0.017). In this study, plasma myeloperoxidase (Spearman's rho=0.421; P=0.004) and nitrate concentration was significantly positively associated with the HbA1c levels while nitrate concentration (Spearman's rho=− 0.308; P=0.047) were was significantly positively negatively associated with the HbA1c levels.

Conclusion Concertation of MPO and nitric oxide were significantly increased in a T2DM subject even when on metformin therapy. However, increased concentration of NO strongly correlates with lower levels of HbA1c showing a postive effect of a gylcemic control on endothelial dysfuction. Increased concentrations of NO3- in T2DM subject compared to control, indicates the variety of NO pathways that should be taken into consideration win relation to endothelial function.

Key words

endothelial dysfunction - cardiovascular disease - inflammation - metabolic disorders - oxidative stress

^* The research was carried out at the School of Medicine, of the University of Mostar, Clinical Institute for Laboratory Diagnosis (Clinical Unit for Multidisciplinary Application of Chromatography), the Clinical Hospital Center Zagreb and the Clinical Laboratory of the University Clinical Hospital Mostar

• References

• 1 Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: The kelly west award lecture 2008. Diabetes Care 2010; 33: 442-449
• 2 Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54: 1615-1625
• 3 Avogaro A, Albiero M, Menegazzo L. et al. Endothelial dysfunction in diabetes: The role of reparatory mechanisms. Diabetes Care 2011; 34 (Suppl. 02) S285-S290
• 4 Tabit CE, Chung WB, Hamburg NM. et al. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74
• 5 Wang Q, Xie Z, Zhang W. et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes 2014; 63: 4172-4185
• 6 Förstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. Eur Heart J 2012; 33: 829-837
• 7 Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424
• 8 Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005; 26: 33-65
• 9 Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20: 295-302
• 10 Vanizor B, Orem A, Karahan SC. et al. Decreased nitric oxide end-products and its relationship with high density lipoprotein and oxidative stress in people with type 2 diabetes without complications. Diabetes Res Clin Pract 2001; 54: 33-39
• 11 Krause M, Rodrigues-Krause J, O'Hagan C. et al. Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: A preliminary study. Metabolism 2012; 61: 1528-1537
• 12 Kataoka Y, Shao M, Wolski K. et al. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. Atherosclerosis 2014; 232: 377-383
• 13 Gómez GA, Rivera RM, Gómez AC. et al. Myeloperoxidase Is associated with insulin resistance and inflammation in overweight subjects with first-degree relatives with type 2 diabetes mellitus. Diabetes & Metabolism Journal 2015; 39: 59-65
• 14 Gorudko IV, Kostevich AV, Sokolov AV. et al. Increased myelopepoxidase activity is a risk factor for ishemic heart disease in patients with diabetes mellitus. Biomed Khim 2012; 58: 475-484
• 15 Li H, Meininger CJ, Wu G. Rapid determination of nitrite by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 2000; 746: 199-207
• 16 Francesconi F, Mingardi R, de Kreutzenberg S. et al. Effect of metabolic control on nitrite and nitrate metabolism in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2001; 28: 518-521
• 17 Apakkan AS, Ozmen B, Ozmen D. et al. Serum and urinary nitric oxide in Type 2 diabetes with or without microalbuminuria: Relation to glomerular hyperfiltration. J Diabetes Complications 2003; 17: 343-348
• 18 Viollet B, Guigas B, Garcia NS. et al. Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond) 2012; 122: 253-270
• 19 Kane DA, Anderson EJ, Price 3rd JW. et al. Metformin selectively attenuates mitochondrial H₂O₂ emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med 2010; 49: 1082-1087
• 20 Rahbar S, Natarajan R, Yerneni K. et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77
• 21 Chukwunonso OB, Chinwuba OT, Okpashi VE. et al. Comparative study of the antioxidant effects of metformin, glibenclamide, and repaglinide in alloxan-induced diabetic rats. J Diabetes Res 2016; 2016: 1635361
• 22 Kotb NA, Gaber R, Salah W. et al. Relations among glycemic control, circulating endothelial cells, nitric oxide, and flow mediated dilation in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120: 460-465
• 23 Van der Zwan LP, Scheffer PG, Dekker JM. et al. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 2010; 55: 1366
• 24 Nita C, Bala C, Porojan M. Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: An open-label interventional study. Diabetol Metab Syndr 2014; 6: 30
• 25 Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001; 34: 583-588
• 26 Dobiasova M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: From research to practice. Vnitr Lek 2006; 52: 64-71
• 27 Samsamshariat SZ, Basati G, Movahedian A. et al. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease. Biomark Med 2011; 5: 377-385
• 28 Zhang C, Yang J, Jennings LK. Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. Diabetes 2004; 53: 2950-2959